SEC Form 4 · accession 0001209191-19-001577
Lineage Cell Therapeutics, Inc. · LCTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Brian M Culley
Officer — President and CEO · Director
Period of report
Jan 1, 2019
Accepted (ET)
Jan 3, 2019 · 8:35 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000876343
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Shares, no par valueF1,F2 | Jan 1, 2019 | M | 100,000 | $0.00 | A | 100,000 | D | |
| Common Shares, no par valueF3,F2 | Jan 1, 2019 | F | 40,880 | $0.913 | D | 59,120 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF4 | $0.00 | Jan 1, 2019 | M | 100,000 | D | — | — | Common Shares | 100,000 | 0 | D |
Explanation of responses
- F1Shares earned by the Reporting Person as a result of the vesting of Restrictive Stock Units ("RSUs") granted to the Reporting Person on September 17, 2018.
- F2Does not include RSUs payable in shares of the Issuer's common stock that have not vested as of the date of this Report and shares that may be acquired upon the exercise of certain stock options.
- F3Securities withheld for tax purposes exempt under Rule 16(b)-3 in connection with the vesting of 100,000 Restricted Stock Units, the grant of which was previously reported on a Form 8-K.
- F4The restricted stock units vested on January 1, 2019.